Drug Profile

Naloxone injection - DMK Pharmaceuticals

Alternative Names: APC 6000; Naloxone HCL injection - DMK Pharmaceuticals; ZIMHI

Latest Information Update: 13 Sep 2023

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Adamis Pharmaceuticals Corporation
Developer DMK Pharmaceuticals
Class Antidotes; Behavioural disorder therapies; Benzofurans; Drug withdrawal therapies; Isoquinolines; Ketones; Laxatives; Morphinans; Small molecules
Mechanism of Action Opioid mu receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Marketed Opioid-related disorders

Most Recent Events

07 Sep 2023 Adamis Pharmaceuticals Corporation is now called DMK Pharmaceuticals
31 Mar 2022 Launched for Opioid-related disorders in USA (IM)
31 Mar 2022 Launched for Opioid-related disorders in USA (SC)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com